WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights.

Discover how BioCryst Pharmaceuticals' patent for complement system inhibitors offers groundbreaking treatment options for various diseases.

which were partially offset by a $15.0 million one-time expense in the first quarter related to the discontinuation of systemic pegcetacoplan for cold agglutinin disease (CAD). Selling, General and ...

Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.

In a note to clients, the analysts at Mizuho cut the firm's price target for the stock to $52 from $60 per share, saying they have updated their model. APLS's stock is currently trading at $43.87, ...

But what was causing the boy's jaundice? After running a number of tests, doctors determined that the boy had cold agglutinin disease, a rare autoimmune disorder in which a person's immune ...

Cold agglutinin disease is under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData, Phase I drugs for Acquired ...

Transfusion of these patients can exacerbate cold agglutinin-mediated haemolysis. Moreover, the workup for these reactions represents a diagnostic challenge due in part to false negative direct ...

Please subscribe to my Seeking Alpha Marketplace Service "Biotech Analysis Central", whereby you can subscribe to either my "Full Tier" at $399/yr or my "Basic Tier" service at $299/yr instead. If ...